Please try another search
For the six months ended 30 September 2013, Oncology Pharma Inc revenues increased from $0K to $19K. Net loss totaled $22M vs. income of $0K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Stock based compensation increase from $0K to $22M (expense), General and administrative expenses increase from $0K to $43K (expense).
Period Ending: | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Sep 30, 2012 |
---|---|---|---|---|
Total Revenue | 0.02 | 0 | 947.89 | 0 |
Gross Profit | 0.02 | 0 | 339.58 | 0 |
Operating Income | -22.02 | 0.02 | 192.78 | 0 |
Net Income | -22.02 | 0.02 | 146.1 | 0 |
Period Ending: | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Sep 30, 2012 |
---|---|---|---|---|
Total Assets | 0.45 | 0.21 | 4953.57 | |
Total Liabilities | 0.62 | 0.4 | 2205.95 | |
Total Equity | -0.17 | -0.18 | 2747.62 |
Period Ending: | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Sep 30, 2012 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 0 Months |
Cash From Operating Activities | 0.04 | 0.01 | 398.52 | |
Cash From Investing Activities | -0.19 | 0 | 252.22 | |
Cash From Financing Activities | 0.15 | -240.3 | ||
Net Change in Cash | -0 | 0.01 | 410.29 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review